@article {Ferreira2021.07.09.21260262, author = {Jos{\'e} Raniery Ferreira, Junior and Victor Henrique Alves Ribeiro and Marcelo Cossetin and Marcus Vin{\'\i}cius Mazega Figueredo and Carolina Queiroz Cardoso and Bernardo Montesanti Almeida}, title = {Time-to-event assessment for the discovery of the proper prognostic value of clinical biomarkers optimized for COVID-19}, elocation-id = {2021.07.09.21260262}, year = {2021}, doi = {10.1101/2021.07.09.21260262}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {In the early days of the pandemic, clinical biomarkers for COVID -19 have been investigated to predict patient mortality. A decision tree has been proposed previously comprising three variables, i.e., lactic dehydrogenase (LDH), high-sensitivity C-reactive protein (CRP), and lymphocyte percentage, with more than 90\% accuracy in a public cohort. In this work, we highlighted the importance of the cohort made publicly available and complemented the findings by incorporating further evaluation. Results confirmed poor short-term prognosis to abnormal levels of some laboratorial indicators, such as LDH, CRP, lymphocytes, interleukin-6, and procalcitonin. In addition, our findings provide insights into COVID-19 research, such as key levels of fibrin degradation products, which are directly associated with the Dimerized plasmin fragment D and could indicate active coagulation and thrombosis. Still, we highlight here the prognostic value of interleukin-6, a cytokine that induces inflammatory response and may serve as a predictive biomarker.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding has been received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB approval was needed as the data used is publicly available.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this work for experiments are publicly available.}, URL = {https://www.medrxiv.org/content/early/2021/07/14/2021.07.09.21260262}, eprint = {https://www.medrxiv.org/content/early/2021/07/14/2021.07.09.21260262.full.pdf}, journal = {medRxiv} }